Prevail Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference
08 August 2019 - 6:00AM
Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology
company developing potentially disease-modifying AAV-based gene
therapies for patients with neurodegenerative disorders, today
announced that Asa Abeliovich, M.D., Ph.D., Founder and CEO, will
present at the 2019 Wedbush PacGrow Healthcare Conference on
Wednesday, August 14, 2019 at 10:20 a.m. ET in New York City.
The live webcast will be available in the investor section of
the company's website at www.prevailtherapeutics.com. The webcast
will be archived for 90 days following the presentation.
About Prevail TherapeuticsPrevail is a gene
therapy company leveraging breakthroughs in human genetics with the
goal of developing and commercializing disease-modifying AAV-based
gene therapies for patients with neurodegenerative diseases.
Prevail was founded by Dr. Asa Abeliovich in 2017, through a
collaborative effort with The Silverstein Foundation for
Parkinson’s with GBA and OrbiMed, and is headquartered in New York,
NY.
Forward-Looking Statements Statements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended.
Examples of these forward-looking statements include statements
concerning: the potential for PR001 to transform the lives of
patients with Parkinson’s disease; the timing of initiation of
Prevail’s Phase 1/2 clinical trial of PR001; and the potential
advantages of FDA’s Fast track designation. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. These risks and uncertainties include, among others:
our novel approach to gene therapy makes it difficult to
predict the time, cost and potential success of product candidate
development or regulatory approval; PR001 may not meet safety and
efficacy levels needed to support ongoing clinical development or
regulatory approval; and the regulatory landscape for gene therapy
is rigorous, complex, uncertain and subject to change. These and
other risks are described more fully in Prevail’s filings with the
Securities and Exchange Commission. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Except to the extent required by law, Prevail
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Media Contact:Katie Engleman1AB
katie@1ABmedia.com
Investor
Contact:investors@prevailtherapeutics.com
Prevail Therapeutics (NASDAQ:PRVL)
Historical Stock Chart
From Apr 2024 to May 2024
Prevail Therapeutics (NASDAQ:PRVL)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Prevail Therapeutics Inc (NASDAQ): 0 recent articles
More News Articles